DocGo Inc. DCGO
DocGo is leading the proactive healthcare revolution. We are democratizing access with our innovative care delivery platform that includes mobile health services, virtual care management and ambulance services. Our goal is to deliver healthcare at any address and help reshape the traditional healthcare system, driven by our mission to bring high quality, highly accessible care to all.
DocGo's proprietary technology platform, dedicated network of certified health professionals, including virtual care clinicians, and robust fleet of medical response vehicles provide services in all 50 states and the United Kingdom. DocGo's vertically integrated approach helps elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. We often provide our services in collaboration with leading healthcare organizations via long-term relationships that are intended to provide efficient and strategic capital deployment opportunities that can drive meaningful revenue and create significant growth.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $322.2M | $616.6M | $624.3M | $440.5M | $318.7M | $94.1M | — |
| Cost of revenue | — | — | — | $523.9M | $451.7M | — | — |
| Gross profit | — | — | — | -$83.4M | -$133.0M | — | — |
| R&D | $13.6M | $11.6M | $10.9M | $5.4M | $3.3M | $1.2M | — |
| SG&A | $133.4M | $138.8M | $137.2M | $103.4M | $74.9M | $34.9M | — |
| Total operating expenses | $500.2M | $587.9M | $609.2M | $418.7M | $303.4M | $108.8M | — |
| Operating income | -$178.0M | $28.7M | $15.1M | $21.8M | $15.4M | -$14.8M | — |
| Interest expense | — | — | $1.7M | $762.7K | $763.0K | $204.6K | — |
| Pre-tax income | -$187.5M | $27.7M | $16.3M | $22.8M | $19.8M | -$14.6M | — |
| Income tax | $8.9M | $14.4M | $6.2M | $8.0M | $615.7K | $167.4K | — |
| Net income | -$196.4M | $13.4M | $10.0M | $30.7M | $19.2M | -$14.8M | — |
| EPS, basic | -1.84 | 0.20 | 0.07 | 0.34 | 0.30 | -0.25 | — |
| EPS, diluted | -1.84 | 0.18 | 0.06 | 0.34 | 0.25 | -0.25 | — |
| Shares, diluted (wtd. avg.) | 99.1M | 109.4M | 105.6M | 103.0M | 94.9M | 58.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $51.0M | $89.2M | $59.3M | $164.1M | $179.1M | $34.5M | $51.8M |
| Receivables | $92.9M | $210.9M | $262.1M | $103.0M | — | — | — |
| Total current assets | $152.4M | $304.5M | $338.9M | $271.1M | $256.0M | $58.4M | — |
| Property, plant and equipment | $14.6M | $14.9M | $16.8M | $21.3M | $12.7M | $9.1M | — |
| Goodwill | $19.0M | $47.4M | $47.5M | $38.9M | $8.7M | $6.6M | — |
| Other intangibles | $0 | $25.7M | $37.7M | $23.0M | $10.7M | $10.7M | — |
| Total assets | $217.1M | $455.6M | $490.5M | $393.3M | $309.6M | $100.2M | — |
| Accounts payable | $11.1M | $28.4M | $19.8M | $21.6M | $15.8M | $4.0M | — |
| Short-term debt | $51.7K | $12.5K | $28.1K | $664.9K | $600.4K | — | — |
| Total current liabilities | $67.5M | $121.8M | $170.1M | $100.2M | $57.9M | $23.5M | — |
| Long-term debt | $183.8K | $5.2K | $41.6K | — | — | $142.7K | — |
| Total liabilities | $91.2M | $140.4M | $185.3M | $114.4M | $82.5M | $33.2M | — |
| Retained earnings | -$183.8M | -$1.4M | -$21.4M | -$29.0M | -$63.6M | -$87.3M | — |
| Total equity | $144.0M | $320.9M | $305.2M | $278.9M | $227.1M | $66.9M | $79.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $34.5M | $70.1M | -$64.5M | $28.9M | -$1.9M | -$10.7M | — |
| Depreciation and amortisation | $15.7M | $15.9M | $16.4M | $10.6M | $2.3M | $1.9M | — |
| Stock-based compensation | $17.4M | $13.6M | $21.0M | $8.1M | $1.4M | — | — |
| Capital expenditure | $4.5M | $3.6M | $7.3M | $3.2M | $4.8M | $4.4M | — |
| Investing cash flow | -$39.1M | -$10.7M | -$29.6M | -$38.4M | -$8.6M | -$6.0M | — |
| Financing cash flow | -$50.8M | -$24.2M | $1.1M | -$6.2M | $155.2M | -$812.1K | — |
| Buybacks | $10.8M | $13.8M | $0 | $3.7M | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-046600.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $94.1M | $318.7M | $440.5M | $624.3M | $616.6M | $322.2M |
| Gross profit | — | — | -$133.0M | -$83.4M | — | — | — |
| Net income | — | -$14.8M | $19.2M | $30.7M | $10.0M | $13.4M | -$196.4M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Delisting notice Item 3.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.94B | — | 13.9% |
| PRVA | Privia Health Group, Inc. | $2.86B | 124.5x | 22.3% |
| WGS | GeneDx Holdings Corp. | $1.67B | — | 40.0% |
| PNTG | Pennant Group, Inc. | $1.46B | 49.9x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.32B | 62.3x | 16.3% |
| INNV | InnovAge Holding Corp. | $1.30B | — | 11.8% |
| OMDA | Omada Health, Inc. | $1.16B | — | 53.2% |
| SRTA | Strata Critical Medical, Inc. | $412.3M | 9.3x | 34.3% |